472 related articles for article (PubMed ID: 30845156)
21. Effect of Patiromer on Hyperkalemia Recurrence in Older Chronic Kidney Disease Patients Taking RAAS Inhibitors.
Weir MR; Bushinsky DA; Benton WW; Woods SD; Mayo MR; Arthur SP; Pitt B; Bakris GL
Am J Med; 2018 May; 131(5):555-564.e3. PubMed ID: 29180023
[TBL] [Abstract][Full Text] [Related]
22. Impact of Sodium Zirconium Cyclosilicate Plus Renin-Angiotensin-Aldosterone System Inhibitor Therapy on Short-Term Medical Costs in Hyperkalemia: OPTIMIZE II Real-World Study.
Dwyer JP; Agiro A; Desai P; Oluwatosin Y
Adv Ther; 2023 Nov; 40(11):4777-4791. PubMed ID: 37606716
[TBL] [Abstract][Full Text] [Related]
23. Prescription of renin-angiotensin-aldosterone system inhibitors (RAASi) and its determinants in patients with advanced CKD under nephrologist care.
Pecoits-Filho R; Fliser D; Tu C; Zee J; Bieber B; Wong MMY; Port F; Combe C; Lopes AA; Reichel H; Narita I; Stengel B; Robinson BM; Massy Z;
J Clin Hypertens (Greenwich); 2019 Jul; 21(7):991-1001. PubMed ID: 31169352
[TBL] [Abstract][Full Text] [Related]
24. Clinical impact of suboptimal RAASi therapy following an episode of hyperkalemia.
Kanda E; Rastogi A; Murohara T; Lesén E; Agiro A; Arnold M; Chen G; Yajima T; Järbrink K; Pollack CV
BMC Nephrol; 2023 Jan; 24(1):18. PubMed ID: 36658531
[TBL] [Abstract][Full Text] [Related]
25. DOPPS data suggest a possible survival benefit of renin angiotensin-aldosterone system inhibitors and other antihypertensive medications for hemodialysis patients.
Karaboyas A; Xu H; Morgenstern H; Locatelli F; Jadoul M; Nitta K; Dasgupta I; Tentori F; Port FK; Robinson BM
Kidney Int; 2018 Sep; 94(3):589-598. PubMed ID: 29908836
[TBL] [Abstract][Full Text] [Related]
26. A cost-effectiveness analysis of patiromer in the UK: evaluation of hyperkalaemia treatment and lifelong RAASi maintenance in chronic kidney disease patients with and without heart failure.
Ward T; Lewis RD; Brown T; Baxter G; de Arellano AR
BMC Nephrol; 2023 Mar; 24(1):47. PubMed ID: 36890464
[TBL] [Abstract][Full Text] [Related]
27. Hyperkalemia and management of renin-angiotensin-aldosterone system inhibitors in chronic heart failure with reduced ejection fraction: A systematic review.
Fonseca C; Brito D; Branco P; Frazão JM; Silva-Cardoso J; Bettencourt P
Rev Port Cardiol (Engl Ed); 2020 Sep; 39(9):517-541. PubMed ID: 32868174
[TBL] [Abstract][Full Text] [Related]
28. Treatment of Abnormalities of Potassium Homeostasis in CKD.
Palmer BF; Clegg DJ
Adv Chronic Kidney Dis; 2017 Sep; 24(5):319-324. PubMed ID: 29031359
[TBL] [Abstract][Full Text] [Related]
29. Association of statin and/or renin-angiotensin-aldosterone system modulating therapy with mortality in adults with diabetes admitted to hospital with COVID-19: A retrospective multicentre European study.
Harris S; Ruan Y; Wild SH; Wargny M; Hadjadj S; Delasalle B; Saignes M; Ryder RE; Field BCT; Narendran P; Zaccardi F; Wilmot EG; Vlacho B; Llauradó G; Mauricio D; Nagi D; Patel D; Várnai KA; Davies J; Gourdy P; Cariou B; Rea R; Khunti K;
Diabetes Metab Syndr; 2022 May; 16(5):102484. PubMed ID: 35472685
[TBL] [Abstract][Full Text] [Related]
30. When should we start and stop ACEi/ARB in paediatric chronic kidney disease?
Chan EY; Ma AL; Tullus K
Pediatr Nephrol; 2021 Jul; 36(7):1751-1764. PubMed ID: 33057769
[TBL] [Abstract][Full Text] [Related]
31. Effectiveness of patiromer in the treatment of hyperkalemia in chronic kidney disease patients with hypertension on diuretics.
Weir MR; Mayo MR; Garza D; Arthur SA; Berman L; Bushinsky D; Wilson DJ; Epstein M
J Hypertens; 2017 May; 35 Suppl 1(Suppl 1):S57-S63. PubMed ID: 28129247
[TBL] [Abstract][Full Text] [Related]
32. Lab monitoring and acute care utilization during initiation of renin angiotensin aldosterone inhibitors or diuretics in chronic kidney disease.
Garlo KG; Bates DW; Seger DL; Fiskio JM; Charytan DM
Medicine (Baltimore); 2019 Dec; 98(49):e17963. PubMed ID: 31804307
[TBL] [Abstract][Full Text] [Related]
33. Development of a health economic model to evaluate the potential benefits of optimal serum potassium management in patients with heart failure.
Bakhai A; Palaka E; Linde C; Bennett H; Furuland H; Qin L; McEwan P; Evans M
J Med Econ; 2018 Dec; 21(12):1172-1182. PubMed ID: 30160541
[TBL] [Abstract][Full Text] [Related]
34. Predictors for repeated hyperkalemia and potassium trajectories in high-risk patients - A population-based cohort study.
Adelborg K; Nicolaisen SK; Hasvold P; Palaka E; Pedersen L; Thomsen RW
PLoS One; 2019; 14(6):e0218739. PubMed ID: 31226134
[TBL] [Abstract][Full Text] [Related]
35. Incidence of and Risk Factors for Severe Adverse Events in Elderly Patients Taking Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers after an Acute Myocardial Infarction.
Fang G; Annis IE; Farley JF; Mahendraratnam N; Hickson RP; Stürmer T; Robinson JG
Pharmacotherapy; 2018 Jan; 38(1):29-41. PubMed ID: 29059475
[TBL] [Abstract][Full Text] [Related]
36. The Effect of Renin-Angiotensin-Aldosterone System Inhibitors on Outcomes of Patients Treated with Immune Checkpoint Inhibitors: a Retrospective Cohort Study.
Chiang CH; Wang SS; Chang YC; Chiang CH; Chen CY; Chen YJ; See XY; Peng CY; Hsia YP; Chiang CH; Peng CM
Clin Oncol (R Coll Radiol); 2023 Jul; 35(7):446-453. PubMed ID: 36894383
[TBL] [Abstract][Full Text] [Related]
37. Adverse effects during treatment with renin-angiotensin-aldosterone system inhibitors; should we stay or should we stop?
Leon SJ; Carrero JJ
Curr Opin Nephrol Hypertens; 2023 May; 32(3):290-296. PubMed ID: 36811640
[TBL] [Abstract][Full Text] [Related]
38. New Therapeutic Approaches for the Treatment of Hyperkalemia in Patients Treated with Renin-Angiotensin-Aldosterone System Inhibitors.
Tamargo J; Caballero R; Delpón E
Cardiovasc Drugs Ther; 2018 Feb; 32(1):99-119. PubMed ID: 29372448
[TBL] [Abstract][Full Text] [Related]
39. Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors.
Weir MR; Bakris GL; Bushinsky DA; Mayo MR; Garza D; Stasiv Y; Wittes J; Christ-Schmidt H; Berman L; Pitt B;
N Engl J Med; 2015 Jan; 372(3):211-21. PubMed ID: 25415805
[TBL] [Abstract][Full Text] [Related]
40. Pooled Analysis of Multiple Crossover Trials To Optimize Individual Therapy Response to Renin-Angiotensin-Aldosterone System Intervention.
Petrykiv SI; Laverman GD; Persson F; Vogt L; Rossing P; de Borst MH; Gansevoort RT; de Zeeuw D; Heerspink HJL
Clin J Am Soc Nephrol; 2017 Nov; 12(11):1804-1813. PubMed ID: 29021336
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
